Novel MEK blocker shows promise in rare genetic disorder ...

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) beat analyst expectations with its third-quarter revenue and earnings figures.

Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales ...

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today ...

Me is restructuring, cutting 40% of its workforce, ending its therapeutics programs, and refocusing on its consumer genetics ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

While not everything appears rosy in one of AstraZeneca’s (LSE: AZN) major markets, the company has announced a huge ...

Twelve leading health economists have published a paper in the Forum for Health Economics and Policy that challenges the drug ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...